WO2008014521A3 - Improved vaccines and methods for using the same - Google Patents
Improved vaccines and methods for using the same Download PDFInfo
- Publication number
- WO2008014521A3 WO2008014521A3 PCT/US2007/074769 US2007074769W WO2008014521A3 WO 2008014521 A3 WO2008014521 A3 WO 2008014521A3 US 2007074769 W US2007074769 W US 2007074769W WO 2008014521 A3 WO2008014521 A3 WO 2008014521A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- those
- consensus sequences
- encode
- nucleic acid
- acid molecules
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title 1
- 108091035707 Consensus sequence Proteins 0.000 abstract 6
- 108020004707 nucleic acids Proteins 0.000 abstract 5
- 102000039446 nucleic acids Human genes 0.000 abstract 5
- 150000007523 nucleic acids Chemical class 0.000 abstract 5
- 101710091045 Envelope protein Proteins 0.000 abstract 4
- 101710188315 Protein X Proteins 0.000 abstract 4
- 102100021696 Syncytin-1 Human genes 0.000 abstract 4
- 206010022000 influenza Diseases 0.000 abstract 2
- 101710177291 Gag polyprotein Proteins 0.000 abstract 1
- 101710125418 Major capsid protein Proteins 0.000 abstract 1
- 108010008038 Synthetic Vaccines Proteins 0.000 abstract 1
- 230000002238 attenuated effect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 229940124551 recombinant vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55538—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- AIDS & HIV (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Tropical Medicine & Parasitology (AREA)
Abstract
Priority Applications (24)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2659262A CA2659262C (en) | 2006-07-28 | 2007-07-30 | Improved hpv vaccines and methods for using the same |
JP2009522035A JP2009544333A (en) | 2006-07-28 | 2007-07-30 | Improved vaccine and method for using the same |
DK07840587.5T DK2049559T3 (en) | 2006-07-28 | 2007-07-30 | Improved HPV vaccines |
KR1020197019662A KR102173636B1 (en) | 2006-07-28 | 2007-07-30 | Improved vaccines and methods for using the same |
KR1020237009029A KR20230042399A (en) | 2006-07-28 | 2007-07-30 | Improved vaccines and methods for using the same |
MX2009001099A MX2009001099A (en) | 2006-07-28 | 2007-07-30 | Improved vaccines and methods for using the same. |
AU2007278831A AU2007278831B2 (en) | 2006-07-28 | 2007-07-30 | Improved vaccines and methods for using the same |
EP07840587A EP2049559B1 (en) | 2006-07-28 | 2007-07-30 | Improved hpv vaccines |
US12/375,518 US8168769B2 (en) | 2006-07-28 | 2007-07-30 | HPV vaccines and methods for using the same |
EP16156199.8A EP3037429B1 (en) | 2006-07-28 | 2007-07-30 | Improved hiv vaccines |
KR1020147035344A KR101609235B1 (en) | 2006-07-28 | 2007-07-30 | Improved vaccines and methods for using the same |
MX2015000975A MX346862B (en) | 2006-07-28 | 2007-07-30 | Improved vaccines and methods for using the same. |
EP21163008.2A EP3907232B1 (en) | 2006-07-28 | 2007-07-30 | Improved hiv vaccines |
CN200780036389.3A CN101679475B (en) | 2006-07-28 | 2007-07-30 | The vaccine improved and using method thereof |
KR1020167007633A KR101710981B1 (en) | 2006-07-28 | 2007-07-30 | Improved vaccines and methods for using the same |
KR1020187010028A KR101999376B1 (en) | 2006-07-28 | 2007-07-30 | Improved vaccines and methods for using the same |
EP18196529.4A EP3489251B1 (en) | 2006-07-28 | 2007-07-30 | Hiv consensus proteins and vaccines made therefrom |
KR1020177004941A KR101848867B1 (en) | 2006-07-28 | 2007-07-30 | Improved vaccines and methods for using the same |
KR1020217039157A KR102511874B1 (en) | 2006-07-28 | 2007-07-30 | Improved vaccines and methods for using the same |
KR1020207031173A KR102334637B1 (en) | 2006-07-28 | 2007-07-30 | Improved vaccines and methods for using the same |
HK09109663.8A HK1130807A1 (en) | 2006-07-28 | 2009-10-20 | Improved hpv vaccines |
US13/458,013 US8697084B2 (en) | 2006-07-28 | 2012-04-27 | HIV consensus envelope sequences and methods for using the same |
US14/139,729 US9376471B2 (en) | 2006-07-28 | 2013-12-23 | HIV consensus envelope sequences and methods for using the same |
US14/139,660 US9290546B2 (en) | 2006-07-28 | 2013-12-23 | hTERT sequences and methods for using the same |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83386106P | 2006-07-28 | 2006-07-28 | |
US83385606P | 2006-07-28 | 2006-07-28 | |
US60/833,861 | 2006-07-28 | ||
US60/833,856 | 2006-07-28 | ||
US89035207P | 2007-02-16 | 2007-02-16 | |
US60/890,352 | 2007-02-16 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/375,518 A-371-Of-International US8168769B2 (en) | 2006-07-28 | 2007-07-30 | HPV vaccines and methods for using the same |
US13/458,013 Division US8697084B2 (en) | 2006-07-28 | 2012-04-27 | HIV consensus envelope sequences and methods for using the same |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2008014521A2 WO2008014521A2 (en) | 2008-01-31 |
WO2008014521A3 true WO2008014521A3 (en) | 2008-12-24 |
WO2008014521A8 WO2008014521A8 (en) | 2012-06-14 |
Family
ID=38982433
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/074769 WO2008014521A2 (en) | 2006-07-28 | 2007-07-30 | Improved vaccines and methods for using the same |
Country Status (12)
Country | Link |
---|---|
US (4) | US8168769B2 (en) |
EP (6) | EP2708549B1 (en) |
JP (8) | JP2009544333A (en) |
KR (9) | KR101562888B1 (en) |
CN (3) | CN105063064A (en) |
AU (3) | AU2007278831B2 (en) |
CA (4) | CA2949851C (en) |
DK (2) | DK2049559T3 (en) |
ES (2) | ES2706501T3 (en) |
HK (2) | HK1130807A1 (en) |
MX (3) | MX346862B (en) |
WO (1) | WO2008014521A2 (en) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101562888B1 (en) * | 2006-07-28 | 2015-10-26 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Improved vaccines and methods for using the same |
US8926961B2 (en) * | 2007-10-03 | 2015-01-06 | Board Of Trustees Of The University Of Arkansas | HPV E6 protein T cell epitopes and uses thereof |
EP2217064A4 (en) * | 2007-11-12 | 2012-10-03 | Univ Pennsylvania | Novel vaccines against multiple subtypes of influenza virus |
CA2653478A1 (en) * | 2009-01-23 | 2010-07-23 | Gregg Martin | Automated wash system for industrial vehicles |
EP2404312A4 (en) | 2009-03-02 | 2013-10-02 | Univ California | DEVICES GROWN ON NONPOLAR OR SEMIPOLAR (Ga,Al,In,B)N SUBSTRATES |
KR20120093163A (en) * | 2009-09-14 | 2012-08-22 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Vaccines and immunotherapeutics comprising il-15 receptor alpha and/or nucleic acid molecules encoding the same, and methods for using the same |
US8298820B2 (en) | 2010-01-26 | 2012-10-30 | The Trustees Of The University Of Pennsylvania | Influenza nucleic acid molecules and vaccines made therefrom |
WO2011097640A1 (en) * | 2010-02-08 | 2011-08-11 | The Trustees Of The University Of Pennsylvania | Nucleic acid molecules encoding rantes, and compositions comprising and methods of using the same |
US9657068B2 (en) | 2010-02-16 | 2017-05-23 | Ultimovacs As | Telomerase polypeptide vaccine for treating cancer |
WO2012040101A1 (en) | 2010-09-21 | 2012-03-29 | University Of Miami | Compositions and methods for inducing migration by dendritic cells and an immune response |
WO2012040266A2 (en) * | 2010-09-24 | 2012-03-29 | University Of Miami | Gene-based adjuvants and compositions thereof to increase antibody production in response to gene-based vaccines |
AU2011316707A1 (en) * | 2010-10-11 | 2013-05-09 | Novartis Ag | Antigen delivery platforms |
KR102216962B1 (en) * | 2011-10-12 | 2021-02-18 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | Vaccines for human papilloma virus and methods for using the same |
US9750795B2 (en) | 2011-12-12 | 2017-09-05 | The Trustees Of The University Of Pennsylvania | Proteins comprising MRSA PBP2a and fragments thereof, nucleic acids encoding the same, and compositions and their use to prevent and treat MRSA infections |
EP2892913A4 (en) * | 2012-09-07 | 2017-01-18 | Agency For Science, Technology And Research | Peptides and their uses |
CN103102394B (en) * | 2013-02-27 | 2014-06-25 | 北京大学人民医院 | B cell epitope peptide PUHI49 for hepatitis c virus (HCV) and application of B cell epitope peptide PUHI49 |
CN103172705B (en) * | 2013-02-27 | 2014-08-20 | 北京大学人民医院 | Hepatitis C virus (HCV) B cell epitope peptide PUHI16 and application thereof |
CN103113458B (en) * | 2013-02-27 | 2014-08-20 | 北京大学人民医院 | Hepatitis c virus B-cell epitope peptide PUHI34 and application thereof |
EA034056B1 (en) | 2013-03-12 | 2019-12-23 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Improved vaccines for human papilloma virus and methods for using the same |
CN114225019A (en) | 2013-03-15 | 2022-03-25 | 宾夕法尼亚大学理事会 | Cancer vaccines and methods of treatment using the same |
WO2015073291A1 (en) * | 2013-11-14 | 2015-05-21 | The Trustees Of The University Of Pennsylvania | Hiv-1 env dna vaccine plus protein boost |
MA40783A (en) | 2014-10-03 | 2017-08-08 | Los Alamos Nat Security Llc | HIV VACCINES CONTAINING ONE OR MORE POPULATION EPISENSUS ANTIGENS |
JP7123800B2 (en) * | 2016-02-05 | 2022-08-23 | イノビオ ファーマシューティカルズ,インコーポレイティド | Cancer vaccine and method of treatment therewith |
CN109069575A (en) * | 2016-02-23 | 2018-12-21 | 毛里齐奥·扎内蒂 | universal cancer vaccine |
AU2017336088B2 (en) | 2016-09-30 | 2023-07-06 | Inovio Pharmaceuticals, Inc. | Tert immunogenic compositions and methods of treatment using the same |
CN110418648B (en) * | 2017-02-22 | 2023-09-08 | 丁恩雨 | mRNA cancer vaccine for encoding fusion of human GM-CSF and multiple tandem epitopes |
CN109142723B (en) * | 2018-08-21 | 2021-07-13 | 苏州华益美生物科技有限公司 | Human immunodeficiency virus rapid detection test card and application thereof |
CN114761041A (en) | 2019-07-16 | 2022-07-15 | 吉利德科学公司 | HIV vaccines and methods of making and using the same |
WO2021202949A2 (en) * | 2020-04-02 | 2021-10-07 | Inovio Pharmaceuticals, Inc. | Compositions and methods for treating vulvar dysplasia |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US21579A (en) | 1858-09-21 | Rotary valve fob steam-engines | ||
US2157994A (en) | 1937-11-08 | 1939-05-09 | Kelsey Hayes Wheel Co | Brake mechanism |
US5077044A (en) | 1980-05-19 | 1991-12-31 | The Board Of Trustees Of The Leland Stanford Jr. University | Novel non-reverting shigella live vaccines |
US5174993A (en) | 1981-12-24 | 1992-12-29 | Health Research Inc. | Recombinant avipox virus and immunological use thereof |
US5338683A (en) | 1981-12-24 | 1994-08-16 | Health Research Incorporated | Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins |
US4722848A (en) * | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
US5110587A (en) | 1981-12-24 | 1992-05-05 | Health Research, Incorporated | Immunogenic composition comprising synthetically modified vaccinia virus |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
US5643579A (en) | 1984-11-01 | 1997-07-01 | American Home Products Corporation | Oral vaccines |
ZA858044B (en) | 1984-11-01 | 1987-05-27 | American Home Prod | Oral vaccines |
US5036006A (en) | 1984-11-13 | 1991-07-30 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
US4945050A (en) * | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
GB8508845D0 (en) * | 1985-04-04 | 1985-05-09 | Hoffmann La Roche | Vaccinia dna |
US5223424A (en) * | 1985-09-06 | 1993-06-29 | Prutech Research And Development | Attenuated herpesviruses and herpesviruses which include foreign DNA encoding an amino acid sequence |
US4790987A (en) | 1985-11-15 | 1988-12-13 | Research Corporation | Viral glycoprotein subunit vaccine |
US5310668A (en) | 1986-06-20 | 1994-05-10 | Merck & Co., Inc. | Varicella-zoster virus as a live recombinant vaccine |
US5242829A (en) * | 1986-09-23 | 1993-09-07 | Therion Biologics Corporation | Recombinant pseudorabies virus |
IL86583A0 (en) | 1987-06-04 | 1988-11-15 | Molecular Eng Ass | Vaccine containing a derivative of a microbe and method for the production thereof |
US5294441A (en) | 1987-06-04 | 1994-03-15 | Washington University | Avirulent microbes and uses therefor: salmonella typhi |
US5387744A (en) | 1987-06-04 | 1995-02-07 | Washington University | Avirulent microbes and uses therefor: Salmonella typhi |
US5112749A (en) | 1987-10-02 | 1992-05-12 | Praxis Biologics, Inc. | Vaccines for the malaria circumsporozoite protein |
CH682669A5 (en) | 1989-03-08 | 1993-10-29 | Health Research Inc | recombinant virus engineered to express a gene product in a host, corresponding methods and vaccine. |
US5225336A (en) | 1989-03-08 | 1993-07-06 | Health Research Incorporated | Recombinant poxvirus host range selection system |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5591439A (en) * | 1989-03-24 | 1997-01-07 | The Wistar Institute Of Anatomy And Biology | Recombinant cytomegalovirus vaccine |
JP3004049B2 (en) | 1989-03-31 | 2000-01-31 | ワシントン ユニバーシティー | Vaccine containing non-pathogenic phoP-type microorganisms |
DE69016956T2 (en) | 1989-12-04 | 1995-07-20 | Akzo Nobel Nv | Recombinant turkey herpes virus and derived live vaccine vector. |
US5294548A (en) | 1990-04-02 | 1994-03-15 | American Biogenetic Sciences, Inc | Recombianant Hepatitis a virus |
WO1991018088A1 (en) * | 1990-05-23 | 1991-11-28 | The United States Of America, Represented By The Secretary, United States Department Of Commerce | Adeno-associated virus (aav)-based eucaryotic vectors |
US5462734A (en) | 1990-11-02 | 1995-10-31 | Wisconsin Alumni Research Foundation | Bovine herpesvirus vaccine and method of using same |
US5240703A (en) | 1991-03-01 | 1993-08-31 | Syntro Corporation | Attenuated, genetically-engineered pseudorabies virus s-prv-155 and uses thereof |
US6034298A (en) | 1991-08-26 | 2000-03-07 | Prodigene, Inc. | Vaccines expressed in plants |
US5955088A (en) | 1992-02-03 | 1999-09-21 | Cedars-Sinai Medical Center | Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1), glycoproteins |
US5981505A (en) | 1993-01-26 | 1999-11-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of genetic material |
US5593972A (en) * | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
ATE302854T1 (en) | 1993-01-26 | 2005-09-15 | Univ Pennsylvania | COMPOSITIONS AND METHODS FOR ADMINISTRATION OF GENETIC MATERIAL |
NZ267838A (en) | 1993-06-07 | 1997-12-19 | Genentech Inc | Preparation of an hiv gp 120 subunit vaccine involving determining a neutralising epitope in the v2 and/or c4 domains |
US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
US6156319A (en) | 1994-07-25 | 2000-12-05 | The Trustees Of The University Of Pennsylvania | Soluble herpesvirus glycoprotein complex vaccine |
NL9401820A (en) * | 1994-11-02 | 1996-06-03 | Meyn Maschf | Device for processing poultry suspended from its legs. |
AUPN015794A0 (en) * | 1994-12-20 | 1995-01-19 | Csl Limited | Variants of human papilloma virus antigens |
US5962428A (en) | 1995-03-30 | 1999-10-05 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
US5650309A (en) * | 1995-05-16 | 1997-07-22 | The Regents Of The University Of California | Viral vectors |
US5698202A (en) | 1995-06-05 | 1997-12-16 | The Wistar Institute Of Anatomy & Biology | Replication-defective adenovirus human type 5 recombinant as a rabies vaccine carrier |
ATE449851T1 (en) * | 1996-10-01 | 2009-12-15 | Geron Corp | HUMAN TELOMERASE REVERSE TRANSCRIPTASE PROMOTER |
US7585622B1 (en) * | 1996-10-01 | 2009-09-08 | Geron Corporation | Increasing the proliferative capacity of cells using telomerase reverse transcriptase |
CN1240480A (en) * | 1996-10-18 | 2000-01-05 | 坎吉有限公司 | Methods and compositions for delivery and expression of interferon-'alpha' nucleic acids |
AUPO517897A0 (en) * | 1997-02-19 | 1997-04-11 | Csl Limited | Chelating immunostimulating complexes |
CA2294782A1 (en) * | 1997-07-01 | 1999-01-14 | Cambia Biosystems Llc | Vertebrate telomerase genes and proteins and uses thereof |
GB9717953D0 (en) * | 1997-08-22 | 1997-10-29 | Smithkline Beecham Biolog | Vaccine |
WO1999013896A1 (en) | 1997-09-18 | 1999-03-25 | The Trustees Of The University Of Pennsylvania | Attenuated vif dna immunization cassettes for genetic vaccines |
US6589529B1 (en) | 1998-10-30 | 2003-07-08 | Children's Hospital Medical Center | Rotavirus subunit vaccine |
CA2415187C (en) * | 2000-07-14 | 2013-06-18 | David B. Weiner | Dna vaccines encoding hiv accessory proteins |
AU2002211524B2 (en) * | 2000-10-04 | 2007-03-22 | The Trustees Of The University Of Pennsylvania | Highly expressible genes |
EP1195438A1 (en) * | 2000-10-06 | 2002-04-10 | Rijksuniversiteit te Groningen | Genetic immunisation against cervical carcinoma |
US7245963B2 (en) | 2002-03-07 | 2007-07-17 | Advisys, Inc. | Electrode assembly for constant-current electroporation and use |
CN1468956A (en) * | 2002-07-15 | 2004-01-21 | 杨 琴 | Recombinant virus of antibody for high-efficiency expression to treat tumor and its use |
CN1315536C (en) * | 2002-09-13 | 2007-05-16 | 李进 | Novel vaccine of tumor antigen, its preparation method and vaccine composition |
AU2003284239B2 (en) | 2002-10-21 | 2008-08-21 | Eisai Inc. | Compositions and methods for treating human papillomavirus-mediated disease |
CN1453361A (en) * | 2003-05-30 | 2003-11-05 | 中国科学院上海生命科学研究院 | Construction method of virus as anticancer targeting adjustable gene |
NZ570709A (en) | 2003-06-13 | 2010-04-30 | Univ Pennsylvania | Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same |
JP4773352B2 (en) * | 2003-09-17 | 2011-09-14 | デューク ユニバーシティ | Consensus / ancestral immunogen |
EP1678292A4 (en) * | 2003-09-18 | 2008-05-07 | Univ Emory | Improved mva vaccines |
KR101562888B1 (en) * | 2006-07-28 | 2015-10-26 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Improved vaccines and methods for using the same |
KR20090079938A (en) * | 2006-10-12 | 2009-07-22 | 이스티투토 디 리세르쉐 디 비올로지아 몰레콜라레 피. 안젤레티에스.피.에이. | Telomerase reverse transcriptase fusion protein, nucleotides encoding it, and uses thereof |
GB2504774A (en) | 2012-08-10 | 2014-02-12 | Munster Simms Eng Ltd | Diaphragm pump with integral motor housing and rear pump housing |
KR20140137679A (en) | 2013-05-23 | 2014-12-03 | 삼성전자주식회사 | Socket for card |
-
2007
- 2007-07-30 KR KR1020097004232A patent/KR101562888B1/en active IP Right Grant
- 2007-07-30 CA CA2949851A patent/CA2949851C/en active Active
- 2007-07-30 KR KR1020167007633A patent/KR101710981B1/en active IP Right Grant
- 2007-07-30 ES ES16156199T patent/ES2706501T3/en active Active
- 2007-07-30 ES ES13187666.6T patent/ES2589013T3/en active Active
- 2007-07-30 EP EP13187666.6A patent/EP2708549B1/en active Active
- 2007-07-30 EP EP18196529.4A patent/EP3489251B1/en active Active
- 2007-07-30 CA CA2659262A patent/CA2659262C/en active Active
- 2007-07-30 US US12/375,518 patent/US8168769B2/en active Active
- 2007-07-30 CN CN201510501034.3A patent/CN105063064A/en active Pending
- 2007-07-30 CA CA3057039A patent/CA3057039C/en active Active
- 2007-07-30 EP EP07840587A patent/EP2049559B1/en active Active
- 2007-07-30 KR KR1020147035344A patent/KR101609235B1/en active Application Filing
- 2007-07-30 KR KR1020177004941A patent/KR101848867B1/en active IP Right Grant
- 2007-07-30 EP EP21163008.2A patent/EP3907232B1/en active Active
- 2007-07-30 KR KR1020217039157A patent/KR102511874B1/en active IP Right Grant
- 2007-07-30 KR KR1020197019662A patent/KR102173636B1/en active IP Right Grant
- 2007-07-30 JP JP2009522035A patent/JP2009544333A/en active Pending
- 2007-07-30 AU AU2007278831A patent/AU2007278831B2/en active Active
- 2007-07-30 KR KR1020207031173A patent/KR102334637B1/en active IP Right Grant
- 2007-07-30 WO PCT/US2007/074769 patent/WO2008014521A2/en active Application Filing
- 2007-07-30 CN CN200780036389.3A patent/CN101679475B/en active Active
- 2007-07-30 DK DK07840587.5T patent/DK2049559T3/en active
- 2007-07-30 CA CA3184778A patent/CA3184778A1/en active Pending
- 2007-07-30 DK DK16156199.8T patent/DK3037429T3/en active
- 2007-07-30 KR KR1020237009029A patent/KR20230042399A/en not_active Application Discontinuation
- 2007-07-30 EP EP16156199.8A patent/EP3037429B1/en active Active
- 2007-07-30 MX MX2015000975A patent/MX346862B/en unknown
- 2007-07-30 KR KR1020187010028A patent/KR101999376B1/en active IP Right Grant
- 2007-07-30 CN CN201510500682.7A patent/CN105132439A/en active Pending
- 2007-07-30 EP EP12197840.7A patent/EP2594576B1/en active Active
- 2007-07-30 MX MX2009001099A patent/MX2009001099A/en active IP Right Grant
-
2009
- 2009-01-28 MX MX2013005334A patent/MX340880B/en unknown
- 2009-10-20 HK HK09109663.8A patent/HK1130807A1/en unknown
-
2012
- 2012-04-27 US US13/458,013 patent/US8697084B2/en active Active
-
2013
- 2013-02-04 JP JP2013019415A patent/JP6097086B2/en active Active
- 2013-03-18 AU AU2013201592A patent/AU2013201592B2/en active Active
- 2013-12-23 US US14/139,660 patent/US9290546B2/en active Active
- 2013-12-23 US US14/139,729 patent/US9376471B2/en active Active
-
2014
- 2014-10-10 JP JP2014208626A patent/JP6186333B2/en active Active
-
2015
- 2015-11-18 JP JP2015225411A patent/JP6356653B2/en active Active
-
2016
- 2016-06-02 HK HK16106306.8A patent/HK1218427A1/en unknown
-
2018
- 2018-03-12 JP JP2018043805A patent/JP2018108110A/en not_active Withdrawn
-
2020
- 2020-03-13 JP JP2020044717A patent/JP7030347B2/en active Active
- 2020-03-13 JP JP2020044718A patent/JP2020103318A/en not_active Withdrawn
-
2022
- 2022-03-22 JP JP2022045506A patent/JP2022081665A/en active Pending
-
2024
- 2024-01-02 AU AU2024200014A patent/AU2024200014A1/en active Pending
Non-Patent Citations (1)
Title |
---|
No relevant documents disclosed * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008014521A8 (en) | Improved vaccines and methods for using the same | |
WO2009026397A3 (en) | Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods | |
WO2007095318A3 (en) | Influenza antigens, vaccine compositions, and related methods | |
EP3199545A3 (en) | Computationally optimized broadly reactive antigens for h1n1 influenza | |
EP3266464A3 (en) | Yeast-based therapeutic for chronic hepatitis b infection | |
WO2008115199A3 (en) | Chimeric virus vaccines | |
WO2011054011A3 (en) | Foot and mouth disease virus (fmdv) consensus proteins, coding sequences therefor and vaccines made therefrom | |
WO2008039267A3 (en) | Inducing cellular immune responses to influenza virus using peptide and nucleic acid compositions | |
EA201190327A1 (en) | NEW CONSTRUCTIONS OF HUMAN PAPILLOMA VIRUS PROTECTION (HPV) AND THEIR APPLICATION IN THE PREVENTION OF DISEASE CAUSED BY HPV | |
ATE527281T1 (en) | VACCINES AGAINST AIDS COMPRISING CMV/R NUCLEIC ACID CONSTRUCTS | |
MX2011009930A (en) | Methods and compositions for immunization against virus. | |
WO2008103380A3 (en) | Hepatitis b virus compositions and methods of use | |
WO2007095320A3 (en) | Hpv antigens, vaccine compositions, and related methods | |
WO2009068992A8 (en) | Vaccination with multiple clades of h5 influenza a virus | |
WO2007085969A3 (en) | Influenza vaccines containing hemagglutinin and matrix proteins | |
MY166953A (en) | Computationally optimized broadly reactive antigens for h5n1 and h1n1 influenza viruses | |
WO2010001409A3 (en) | Vaccine composition useful for hpv and hepatitis b infections and a method for preparing the same | |
CL2012000447A1 (en) | Composition or vaccine comprising a recombinant avian paramyxovirus 8 (apmv-8) viral vector; method of producing said vector; and use to prepare medicament useful for inducing an immune response. | |
WO2009026465A3 (en) | Composition and methods of making and using influenza proteins | |
WO2006131936A3 (en) | Hepatitis c virus vaccine | |
MX359981B (en) | Recombinant measles virus expressing chikungunya virus polypeptides and their applications. | |
MX2011007692A (en) | Improved vaccines for human papilloma virus and methods for using the same. | |
WO2015195218A8 (en) | Polyvalent influenza virus-like particles (vlps) and use as vaccines | |
CA2863981A1 (en) | Computationally optimized broadly reactive antigens for h3n2, h2n2, and b influenza viruses | |
AU2013352179A8 (en) | Computationally optimized broadly reactive antigens for H1N1 influenza |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780036389.3 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07840587 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2659262 Country of ref document: CA Ref document number: 2009522035 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007278831 Country of ref document: AU Ref document number: MX/A/2009/001099 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2007278831 Country of ref document: AU Date of ref document: 20070730 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 688/KOLNP/2009 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007840587 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020097004232 Country of ref document: KR |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12375518 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020147035344 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020167007633 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020177004941 Country of ref document: KR |